Nancee Pronsati and Kenneth Culver
Aug 5, 2025, 12:39
Lorlatinib as First Treatment for ALK+ Lung Cancer – ALK Positive Inc.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 13:49
Aug 25, 2025, 12:37
Aug 25, 2025, 12:23
Aug 25, 2025, 11:07
Aug 25, 2025, 09:45
ALK Positive Inc. shared a post on LinkedIn:
“Following the CROWN study, many people in our ALK+ lung cancer community are starting lorlatinib as their first treatment. Others may move to lorlatinib after earlier lines of therapy.
We know managing side effects can feel daunting — but you’re not alone.
Working together with renowned physicians, our Vice President, Nancee Pronsati, and our Director of Research and Clinical Affairs, Kenneth Culver, co-authored a practical guide in Science Direct. This brings a for patients by patients perspective, to break down what to expect, how to manage side effects, and how to protect your quality of life.
In this post, we share the key takeaways to help you feel informed and prepared.
Save this post for reference — and read the full article on our website too.”
Watch the video attached to this post.
Oncogene Cancer Research shared a post on LinkedIn by ALK Positive Inc., adding:
“Practical, patient-led information like this makes a real difference. Many people with ALK+ lung cancer are now starting lorlatinib as a first-line treatment or later in their care. Managing side effects and protecting quality of life matter every step of the way.
This new guide from our friends at ALK Positive Inc., co-authored with Dr. Kenneth Culver, and Vice President Nancee Pronsati, breaks down what patients and families need to know — in plain language, by patients, for patients.
Well worth saving and sharing.”
More posts featuring ALK Positive Inc and Oncogene Cancer Research on OncoDaily.